Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Tofacitinib citrate
Cat. No.:
OB0225LY-0232
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Tofacitinib citrate is an oral small molecule drug that inhibits specific tyrosine kinases and affects the function of the immune system.
Synonym:
CP-690550 citrate; Tasocitinib citrate; Tofacitinib (CP-690550) citrate; 540737-29-9; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate; 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)- beta-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
CAS No.:
540737-29-9
Compound CID:
10174505
Formula:
C22H28N6O8
Formula Weight:
504.49
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Tofacitinib citrate can be used to study immunoregulatory mechanisms.
Library Information
Targets:
JAK family
Receptors:
JAK1; JAK2; JAK3
Pathways:
Angiogenesis; JAK/STAT signaling; Stem cells; Apoptosis; Chromatin/Epigenetic; Microbiology/Virology
Plate Number:
AOCL-3
Plate Location:
h6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 109.02 mM
ALogP:
0.193
HBA_Count:
6
HBD_Count:
1
Rotatable Bond:
8
